Skip to main content

Main menu

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Subscribers
    • Advertisers
    • Editorial Board
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics

User menu

  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Anticancer Research
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics
  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Anticancer Research

Advanced Search

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Subscribers
    • Advertisers
    • Editorial Board
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Visit us on Facebook
  • Follow us on Linkedin

irinotecan

  • You have access
    Experimental Exploration for Genes Related to Susceptibility and Resistance to Irinotecan
    SUGURU OGATA, TOMOYA SUDOU, FUMIHIKO FUJITA, TAKEFUMI YOSHIDA, KENICHI KOUSHI, TAKASHI NOGUCHI, JUNYA FUKUDA, NANAE OGATA, YOSHITAKA NOBUKUNI and YOSHITO AKAGI
    Anticancer Research August 2022, 42 (8) 4011-4016; DOI: https://doi.org/10.21873/anticanres.15897
  • You have access
    Phase II Study of S-1 and Irinotecan Plus Bevacizumab as Second-line Treatment for Patients With Metastatic Colorectal Cancer Resistant to the Fluoropyrimidine-oxaliplatin-cetuximab Regimen
    HIROAKI TANIOKA, KEN SHIMADA, AKIHITO TSUJI, MITSUGU KOCHI, HO MIN KIM, TAKAO TAKAHASHI, TADAMICHI DENDA, AKINORI TAKAGANE, TAKANORI WATANABE, MASAHITO KOTAKA, MASATO NAKAMURA, YU SUNAKAWA, MASAHIRO TAKEUCHI, WATARU ICHIKAWA and MASASHI FUJII
    Anticancer Research May 2022, 42 (5) 2675-2681; DOI: https://doi.org/10.21873/anticanres.15745
  • You have access
    CHFR-Promoter-Methylation Status Is Predictive of Response to Irinotecan-based Systemic Chemotherapy in Advanced Colorectal Cancer
    TOSHIAKI HAGIWARA, KIICHI SUGIMOTO, HIROTAKA MOMOSE, TAKAHIRO IRIE, KUMPEI HONJO, YU OKAZAWA, MASAYA KAWAI, SHINGO KAWANO, SHINYA MUNAKATA, MAKOTO TAKAHASHI, YUTAKA KOJIMA, NOBUKO SERIZAWA, AKIHITO NAGAHARA, ROBERT M. HOFFMAN, MALCOLM V. BROCK and KAZUHIRO SAKAMOTO
    Anticancer Research February 2022, 42 (2) 697-707; DOI: https://doi.org/10.21873/anticanres.15528
  • You have access
    Pilot Study of Irinotecan and S-1 (IRIS) for Advanced and Metastatic Breast Cancer
    TOSHIHIRO TANAKA, MAKI TANAKA, HIDEMI FURUSAWA, YOSHIHIKO KAMADA, YOSHIAKI SAGARA, KEISEI ANAN, KYUICHIROU MIYARA, YUICHIROU KAI, TATSUYA UGA, KAZUO TAMURA, SHOSHU MITSUYAMA and KBC-SG (Kyushu Breast Cancer-Study Group)
    Anticancer Research August 2020, 40 (8) 4779-4785; DOI: https://doi.org/10.21873/anticanres.14480
  • You have access
    Combination of Trabectedin With Irinotecan, Leucovorin and 5-Fluorouracil Arrests Primary Colorectal Cancer in an Imageable Patient-derived Orthotopic Xenograft Mouse Model
    GUANGWEI ZHU, MING ZHAO, QINGHONG HAN, YUYING TAN, YU SUN, MICHAEL BOUVET, BRYAN CLARY, SHREE RAM SINGH, JIANXIN YE and ROBERT M. HOFFMAN
    Anticancer Research December 2019, 39 (12) 6463-6470; DOI: https://doi.org/10.21873/anticanres.13860
  • You have access
    A Phase II Study Alternating Erlotinib With Second-line mFOLFOX6 or FOLFIRI for Metastatic Colorectal Cancer
    MATTHEW R. KEARNEY, EMERSON Y. CHEN, GINA M. VACCARO, JOHN STROTHER, ANDREA BURT, KENDRA TODD, JEFF DONOVAN, KERSTIN M. KAMPA-SCHITTENHELM and CHARLES D. LOPEZ
    Anticancer Research January 2019, 39 (1) 245-252; DOI: https://doi.org/10.21873/anticanres.13104
  • You have access
    Patients with hMLH1 or/and hMSH2-deficient Metastatic Colorectal Cancer Are Associated with Reduced Levels of Vascular Endothelial Growth Factor-1 Expression and Higher Response Rate to Irinotecan-based Regimen
    RIYAD BENDARDAF, FATEMEH SAHEB SHARIF-ASKARI, NARJES SAHEB SHARIF-ASKARI, KARI SYRJÄNEN and SEPPO PYRHÖNEN
    Anticancer Research November 2018, 38 (11) 6399-6404; DOI: https://doi.org/10.21873/anticanres.13000
  • You have access
    Preexisting Interstitial Lung Disease and Lung Injury Associated with Irinotecan in Patients with Neoplasms
    YUICHI OZAWA, KEIGO KODA, DAISUKE AKAHORI, TAKASHI MATSUI, HIROTSUGU HASEGAWA, TAKUYA KAKUTANI, TUSUKE AMANO, MASAYUKI TANAHASHI, HIROSHI NIWA, YUKIHIRO KUNIMOTO, KAZUNARI YAMADA, KOSHI YOKOMURA and TAKAFUMI SUDA
    Anticancer Research October 2018, 38 (10) 5937-5941; DOI: https://doi.org/10.21873/anticanres.12939
  • You have access
    Irinotecan and Oxaliplatin Might Provide Equal Benefit as Adjuvant Chemotherapy for Patients with Resectable Synchronous Colon Cancer and Liver-confined Metastases: A Nationwide Database Study
    YI-HSIN LIANG, YU-YUN SHAO, HO-MIN CHEN, ANN-LII CHENG, MEI-SHU LAI and KUN-HUEI YEH
    Anticancer Research December 2017, 37 (12) 7095-7104;
  • You have access
    Survival Outcomes According to TIMP1 and EGFR Expression in Heavily Treated Patients with Advanced Non-small Cell Lung Cancer who Received Biweekly Irinotecan Plus Bevacizumab
    BEATRIZ WILLS, ANDRÉS F. CARDONA, LEONARDO ROJAS, ALEJANDRO RUIZ-PATIÑO, OSCAR ARRIETA, NOEMÍ REGUART, HERNÁN CARRANZA, CARLOS VARGAS, JORGE OTERO, LUIS CORRALES, CLAUDIO MARTÍN, MAURICIO CUELLO, LUIS EDUARDO PINO, CHRISTIAN ROLFO, RAFAEL ROSELL, ZYANYA LUCIA ZATARAIN-BARRÓN and on behalf of The Latin-American Consortium for the Investigation of Lung Cancer (CLICaP)
    Anticancer Research November 2017, 37 (11) 6429-6436;

Pages

  • Next
  • 1
  • 2
  • 3
  • 4
Anticancer Research

© 2022 Anticancer Research

Powered by HighWire